Eugene P van Puijenbroek (Eugène van Puijenbroek, Eugene van Puijenbroek, Eugène P van Puijenbroek)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 32

Top Topics

Chronic Obstructive Pulmonary Disease

Electronic Health Record

Top Venues

Archives of women's mental health

Expert opinion on drug safety

Pharmacoepidemiology and drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Yrea R J van Rijt-Weetink, Antoine C G Egberts, Florence P A M van Hunsel, David John Lewis, Laura M Yates, Ursula Winterfeld, Eugene P van Puijenbroek
Validation of a Novel Method to Assess the Clinical Quality of Information in Pregnancy-Related Pharmacovigilance Case Reports: A ConcePTION Project. Drug safety 47 (3) (2024)
Yrea R J van Rijt-Weetink, Antoine C G Egberts, Florence P A M van Hunsel, David John Lewis, Laura M Yates, Ursula Winterfeld, Eugene P van Puijenbroek
Validation of a Novel Method to Assess the Clinical Quality of Information in Pregnancy-Related Pharmacovigilance Case Reports: A ConcePTION Project. Drug safety 47 (3) (2024)
Eugene P van Puijenbroek, Abbie Barry, Christabel Khaemba, Lazare Ntirenganya, Tigist Dires Gebreyesus, Adam Mitangu Fimbo, Omary M S Minzi, Eyasu Mekonnen Eshetu, Margaret N Oluka, Anastasia Guantai, Eleni Aklillu
Short-Term Training, a Useful Approach for Sustainable Pharmacovigilance Knowledge Development in Tanzania, Kenya, Ethiopia and Rwanda. Drug safety (2024)
Yrea R J van Rijt-Weetink, Antoine C G Egberts, Florence P A M van Hunsel, David John Lewis, Laura M Yates, Ursula Winterfeld, Eugene P van Puijenbroek
Validation of a Novel Method to Assess the Clinical Quality of Information in Pregnancy-Related Pharmacovigilance Case Reports: A ConcePTION Project. Drug safety (2024)
Yrea R J van Rijt-Weetink, Antoine C G Egberts, Florence P A M van Hunsel, David John Lewis, Laura M Yates, Ursula Winterfeld, Eugene P van Puijenbroek
Validation of a Novel Method to Assess the Clinical Quality of Information in Pregnancy-Related Pharmacovigilance Case Reports: A ConcePTION Project. Drug safety 47 (3) (2024)
Robiyanto Robiyanto, Catharina C M Schuiling-Veninga, Jens H J Bos, Eelko Hak, Eugene P van Puijenbroek
Exposure to psychotropic drugs before and during pregnancy: what has changed over the last two decades? Archives of women's mental health 26 (1) (2023)
Robiyanto Robiyanto, Catharina C M Schuiling-Veninga, Jens H J Bos, Eelko Hak, Eugene P van Puijenbroek
Exposure to psychotropic drugs before and during pregnancy: what has changed over the last two decades? Archives of women's mental health 26 (1) (2023)
Robiyanto Robiyanto, Marjolein Roos, Jens H J Bos, Eelko Hak, Eugene P van Puijenbroek, Catharina C M Schuiling-Veninga
Switching pattern and dose adjustment of antidepressants before and during pregnancy. Archives of women's mental health (2023)
Robiyanto Robiyanto, Catharina C M Schuiling-Veninga, Jens H J Bos, Eelko Hak, Eugene P van Puijenbroek
Exposure to psychotropic drugs before and during pregnancy: what has changed over the last two decades? Archives of women's mental health 26 (1) (2023)
Robiyanto Robiyanto, Catharina C M Schuiling-Veninga, Jens H J Bos, Eelko Hak, Eugene P van Puijenbroek
Exposure to psychotropic drugs before and during pregnancy: what has changed over the last two decades? Archives of women's mental health 26 (1) (2023)
Robiyanto Robiyanto, Catharina C M Schuiling-Veninga, Jens H J Bos, Eelko Hak, Eugene P van Puijenbroek
Exposure to psychotropic drugs before and during pregnancy: what has changed over the last two decades? Archives of women's mental health (2023)
Jonathan Luke Richardson, Alan Moore, Rebecca Louise Bromley, Michael Stellfeld, Yvonne Geissbühler, Matthew Bluett-Duncan, Ursula Winterfeld, Guillaume Favre, Amalia Alexe, Alison M Oliver, Yrea R J van Rijt-Weetink, Kenneth K Hodson, Bita Rezaallah, Eugene P van Puijenbroek, David John Lewis, Laura M Yates
Core Data Elements for Pregnancy Pharmacovigilance Studies Using Primary Source Data Collection Methods: Recommendations from the IMI ConcePTION Project. Drug safety (2023)
Robiyanto Robiyanto, Catharina C M Schuiling-Veninga, Jens H J Bos, Eelko Hak, Eugene P van Puijenbroek
Exposure to psychotropic drugs before and during pregnancy: what has changed over the last two decades? Archives of women's mental health 26 (1) (2023)
Isa P A C Geeven, Naomi T Jessurun, Arthur T M Wasylewicz, Marjolein Drent, Phyllis I Spuls, Frank Hoentjen, Eugene P van Puijenbroek, Harald E Vonkeman, Koen P Grootens, Martijn Bastiaan Adriaan van Doorn, Bart J F van Den Bemt, Charlotte L Bekker
Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals. Expert opinion on drug safety 21 (5) (2022)
Ingrid Oosterhuis, Joep H G Scholl, Eugene P van Puijenbroek, Agnes C Kant, Florence P A M van Hunsel
Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience. Drug safety (2022)
Lieke H Roest, Leanne J Kosse, Jette A van Lint, Helen R Gosselt, Joep H G Scholl, Eugene P van Puijenbroek, Harald E Vonkeman, Sander W Tas, Michael T Nurmohamed, Bart J F van den Bemt, Naomi T Jessurun
Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study. Expert opinion on drug safety (2022)
Karin Hek, Agnes Kant, Eugene P van Puijenbroek, Linda E Flinterman, Saskia Vorstenbosch, Liset van Dijk, Robert A Verheij
Electronic Health Record-Triggered Research Infrastructure Combining Real-world Electronic Health Record Data and Patient-Reported Outcomes to Detect Benefits, Risks, and Impact of Medication: Development Study. JMIR medical informatics 10 (3) (2022)
Corine Ekhart, Florence P A M van Hunsel, Eugene P van Puijenbroek, Rebecca E Chandler, Eva-Lisa Meldau, Henric Taavola, G Niklas Norén
Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports. Drug safety 45 (2) (2022)
Sieta T de Vries, Petra Denig, Corine Ekhart, Peter G M Mol, Eugene P van Puijenbroek
Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study. Drug safety 43 (5) (2021)
Leanne J Kosse, Gerda Weits, Harald E Vonkeman, Sander W Tas, Frank Hoentjen, Martijn Bastiaan Adriaan van Doorn, Phyllis I Spuls, Geert R A M D'Haens, Michael T Nurmohamed, Eugene P van Puijenbroek, Bart Jf Van Den Bemt, Naomi T Jessurun
Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. Expert opinion on drug safety 20 (12) (2021)
Tanja Fens, Guiling Zhou, Maarten Jacobus Postma, Eugene P van Puijenbroek, Job Frank Martien van Boven
Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed? Expert opinion on pharmacotherapy 22 (7) (2021)
Jette A van Lint, Tom Bakker, Peter M Ten Klooster, Eugene P van Puijenbroek, Harald E Vonkeman, Naomi T Jessurun
Neuropsychiatric adverse drug reactions associated with low dose methotrexate in rheumatoid arthritis patients. Expert opinion on drug safety (2021)
Jette A van Lint, Florence P A M van Hunsel, Sander W Tas, Harald E Vonkeman, Frank Hoentjen, Martijn Bastiaan Adriaan van Doorn, Renske C F Hebing, Michael T Nurmohamed, Bart J F van den Bemt, Eugene P van Puijenbroek, Naomi T Jessurun
Hypoglycaemia following JAK inhibitor treatment in patients with diabetes. Annals of the rheumatic diseases 81 (4) (2021)
Abbie Barry, Sten Olsson, Omary Minzi, Emile Bienvenu, Eyasu Mekonnen Eshetu, Appolinary Kamuhabwa, Margaret Oluka, Anastasia Guantai, Ulf Bergman, Eugene P van Puijenbroek, Parthasarathi Gurumurthy, Eleni Aklillu
Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Drug safety 43 (4) (2021)
Eline L Giraud, Naomi T Jessurun, Florence P A M van Hunsel, Eugene P van Puijenbroek, Astrid van Tubergen, Peter M Ten Klooster, Harald E Vonkeman
Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients. Expert opinion on drug safety 19 (12) (2020)
Petra Denig, Eugene P van Puijenbroek, Nashwa Soliman, Peter G M Mol, Sieta T de Vries
Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care. Pharmacoepidemiology and drug safety 28 (9) (2019)
Joep H G Scholl, Florence P A M van Hunsel, Eelko Hak, Eugene P van Puijenbroek
Time to onset in statistical signal detection revisited: A follow-up study in long-term onset adverse drug reactions. Pharmacoepidemiology and drug safety 28 (10) (2019)
Sieta T de Vries, Petra Denig, Corine Ekhart, Jako S Burgers, Nanne Kleefstra, Peter G M Mol, Eugene P van Puijenbroek
Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. British journal of clinical pharmacology 85 (7) (2019)
Corine Ekhart, Florence P A M van Hunsel, Joep H G Scholl, Sieta T de Vries, Eugene P van Puijenbroek
Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors. Drug safety 41 (7) (2018)
Florence P A M van Hunsel, Sonja van de Koppel, Eugene P van Puijenbroek, Agnes Kant
Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases. Drug safety 41 (9) (2018)
Agnes Kant, Florence P A M van Hunsel, Ola Caster, Henric Taavola, Katka Taxis, Eugene P van Puijenbroek
Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database. British journal of clinical pharmacology 84 (7) (2018)
Joep H G Scholl, Florence P A M van Hunsel, Eelko Hak, Eugene P van Puijenbroek
A prediction model-based algorithm for computer-assisted database screening of adverse drug reactions in the Netherlands. Pharmacoepidemiology and drug safety 27 (2) (2017)